Patents Assigned to Voyager Therapeutics, Inc.
  • Modulatory polynucleotides
    Patent number: 11198873
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: December 14, 2021
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou
  • Modulatory polynucleotides
    Patent number: 11193129
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: December 7, 2021
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher
  • CLOSED-ENDED LINEAR DUPLEX DNA FOR NON-VIRAL GENE TRANSFER
    Publication number: 20210355507
    Abstract: Aspects of the disclosure relate to a nucleic acid comprising a heterologous nucleic acid insert flanked by interrupted self-complementary sequences, wherein one self-complementary sequence is interrupted by a cross-arm sequence forming two opposing, lengthwise-symmetric stem-loops, and wherein the other of the self-complementary sequences is interrupted by a truncated cross-arm sequence. Methods of delivering the nucleic acid to a cell are also provided.
    Type: Application
    Filed: June 1, 2021
    Publication date: November 18, 2021
    Applicants: University of Massachusetts, Voyager Therapeutics, Inc.
    Inventors: Robert M. Kotin, Sylvain Cecchini
  • AAV SEROTYPES FOR BRAIN SPECIFIC PAYLOAD DELIVERY
    Publication number: 20210207167
    Abstract: The present disclosure relates to compositions, methods, and processes for the design, preparation, manufacture, use, and/or formulation of adeno-associated virus (AAV) particles for improved biodistribution and/or expression to particular regions of the central nervous system (CNS).
    Type: Application
    Filed: May 16, 2019
    Publication date: July 8, 2021
    Applicant: Voyager Therapeutics, Inc.
    Inventors: Jinzhao HOU, Kei ADACHI
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20210198691
    Abstract: The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of polynucleotides encoding AADC. The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of AAV vectors which include polynucleotides encoding AADC. The present disclosure relates to methods, formulations and devices for the delivery and therapeutic administration of polynucleotides encoding AADC in the treatment of neurological diseases, disorders and conditions, including Parkinson's Disease.
    Type: Application
    Filed: May 15, 2019
    Publication date: July 1, 2021
    Applicant: Voyager Therapeutics, Inc.
    Inventors: Bernard RAVINA, Adrian Philip KELLS
  • AADC polynucleotides for the treatment of Parkinson's disease
    Patent number: 11027000
    Abstract: The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: June 8, 2021
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Robert Kotin, Adrian Philip Kells, Bernard Ravina
  • Assays for the detection of AAV neutralizing antibodies
    Patent number: 10983110
    Abstract: The present invention relates to improved methods and assays for the detection of AAV neutralizing antibodies in sera. The present invention provides safe, sensitive and high throughput neutralization assays for antibody detection.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: April 20, 2021
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Tatiana I. Novobrantseva, Dinah Wen-Yee Sah
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 10920227
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: February 16, 2021
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Compositions and methods of treating amyotrophic lateral sclerosis (ALS)
    Patent number: 10597660
    Abstract: The present invention relates to small interfering RNA (siRNA) molecules against the SOD1 gene, adeno-associated viral (AAV) vectors encoding siRNA molecules and methods for treating amyotrophic lateral sclerosis (ALS) using the siRNA molecules and AAV vectors.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: March 24, 2020
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou, Markus Hossbach, Jochen Deckert
  • Modulatory polynucleotides
    Patent number: 10584337
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: March 10, 2020
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Dinah Wen-Yee Sah, Jinzhao Hou, Mathieu Nonnenmacher
  • Chimeric capsids
    Patent number: 10577627
    Abstract: The present invention relates to viral vectors and methods of their production and use.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: March 3, 2020
    Assignee: Voyager Therapeutics, Inc.
    Inventors: Robert Kotin, Jinzhao Hou, James McLaughlin
  • Modulatory polynucleotides
    Patent number: 10570395
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: February 25, 2020
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Jinzhao Hou, Mathieu E. Nonnenmacher, Pengcheng Zhou
  • AADC polynucleotides for the treatment of parkinson's disease
    Patent number: 10335466
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: July 2, 2019
    Assignee: VOYAGER THERAPEUTICS, INC.
    Inventors: Robert Kotin, Adrian Philip Kells, Bernard Ravina
  • DELIVERY OF CENTRAL NERVOUS SYSTEM TARGETING POLYNUCLEOTIDES
    Publication number: 20190055578
    Abstract: The invention relates to compositions and methods for the preparation, administration, manufacture and therapeutic use of viral particles for the treatment of CNS disorders.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 21, 2019
    Applicant: Voyager Therapeutics, Inc.
    Inventors: Dinah Wen-Yee SAH, Jinzhao HOU, Martin GOULET, Adrian Philip KELLS, Pengcheng ZHOU, Gregory Robert STEWART
  • ASSAYS FOR THE DETECTION OF AAV NEUTRALIZING ANTIBODIES
    Publication number: 20180356394
    Abstract: The present invention relates to improved methods and assays for the detection of AAV neutralizing antibodies in sera. The present invention provides safe, sensitive and high throughput neutralization assays for antibody detection.
    Type: Application
    Filed: December 2, 2016
    Publication date: December 13, 2018
    Applicant: Voyager Therapeutics, Inc.
    Inventors: Tatiana I. NOVOBRANTSEVA, Dinah Wen-Yee SAH
  • REGULATABLE EXPRESSION USING ADENO-ASSOCIATED VIRUS (AAV)
    Publication number: 20180230489
    Abstract: The present invention relates to viral particles which exhibit self-regulatory or regulatable features.
    Type: Application
    Filed: October 28, 2016
    Publication date: August 16, 2018
    Applicant: Voyager Therapeutics, Inc.
    Inventor: Robert KOTIN